Rivaroxaban or Placebo for Extended Antithrombotic Prophylaxis After Laparoscopic Surgery for Colorectal Cancer. (PRO-LAPSII)
Rivaroxaban or Placebo for Extended Antithrombotic Prophylaxis After Laparoscopic Surgery for Colorectal Cancer: a Randomized, Double Blind, Placebo-controlled Study.
Sponsor: Fadoi Foundation, Italy
This PHASE3 trial investigates Prevention of Venous Thromboembolism and is currently completed. Fadoi Foundation, Italy leads this study, which shows 10 recorded versions since 2017 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE3
Status: Unknown Status → Completed
-
Oct 2021 — Apr 2022 [monthly]
Unknown Status PHASE3
Status: Recruiting → Unknown Status
▶ Show 5 earlier versions
-
Jan 2021 — Oct 2021 [monthly]
Recruiting PHASE3
-
Jul 2019 — Jan 2021 [monthly]
Recruiting PHASE3
-
Jun 2018 — Jul 2019 [monthly]
Recruiting PHASE3
-
Jun 2017 — Jun 2018 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Feb 2017 — Jun 2017 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Fadoi Foundation, Italy
- University Of Perugia
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Arezzo, Italy , Castelfranco Veneto, Italy , Castellanza, Italy , Cittadella, Italy , Florence, Italy , Foligno, Italy , Napoli, Italy , Padua, Italy , Perugia, Italy , Pesaro, Italy and 6 more locations